WINTON GROUP Ltd bought a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 121,320 shares of the company’s stock, valued at approximately $10,316,000. WINTON GROUP Ltd owned about 0.08% of Henry Schein as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in HSIC. NEXT Financial Group Inc purchased a new stake in shares of Henry Schein during the third quarter valued at $103,000. McAdam LLC purchased a new stake in shares of Henry Schein during the third quarter valued at $104,000. Squar Milner Financial Services LLC purchased a new stake in shares of Henry Schein during the second quarter valued at $120,000. Piedmont Investment Advisors LLC purchased a new stake in shares of Henry Schein during the second quarter valued at $130,000. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Henry Schein by 57.1% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock valued at $160,000 after purchasing an additional 800 shares during the last quarter.
Shares of HSIC stock opened at $85.43 on Friday. The company has a current ratio of 1.30, a quick ratio of 0.68 and a debt-to-equity ratio of 0.29. Henry Schein, Inc. has a fifty-two week low of $62.56 and a fifty-two week high of $90.52. The stock has a market capitalization of $13.31 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 2.71 and a beta of 0.87.
Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 6th. The company reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.02. Henry Schein had a return on equity of 20.40% and a net margin of 3.00%. The company had revenue of $3.28 billion for the quarter, compared to analyst estimates of $3.37 billion. During the same period in the prior year, the firm posted $0.87 EPS. The business’s revenue was up 3.8% compared to the same quarter last year. Equities research analysts expect that Henry Schein, Inc. will post 4.12 earnings per share for the current fiscal year.
Several equities research analysts have recently commented on the company. BidaskClub downgraded Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 23rd. Barrington Research reaffirmed a “buy” rating and set a $92.00 target price on shares of Henry Schein in a report on Tuesday, August 7th. ValuEngine raised Henry Schein from a “strong sell” rating to a “sell” rating in a report on Thursday, September 13th. Stifel Nicolaus upped their target price on Henry Schein from $76.00 to $81.00 and gave the company a “hold” rating in a report on Tuesday, August 7th. Finally, Zacks Investment Research raised Henry Schein from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a report on Wednesday, July 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Henry Schein currently has an average rating of “Hold” and an average target price of $84.41.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Story: Retained Earnings
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.